U.S. Online Retail and Ecommerce Stock News

NasdaqGS:NDAQ
NasdaqGS:NDAQCapital Markets

Nasdaq (NDAQ) Margin Jump To 21.8% Tests High Valuation Narratives

NasdaqGS:NDAQ just closed out FY 2025 with fourth quarter revenue of US$2.1b and basic EPS of US$0.18, alongside trailing twelve month revenue of US$8.2b and EPS of US$1.56 that frame the full year picture. The company has seen revenue move from US$7.4b to US$8.2b over the latest trailing periods, with trailing EPS shifting from US$1.94 to US$1.56. This gives investors a clear read on how the top line and per share earnings have tracked into this result. With net profit margin running at...
NasdaqGS:TOWN
NasdaqGS:TOWNBanks

TowneBank (TOWN) Net Interest Margin Gain Tests Bullish Earnings Narratives

TowneBank (TOWN) has wrapped up FY 2025 with fourth quarter total revenue of US$220.1 million and basic EPS of US$0.52, alongside trailing twelve month revenue of US$811.8 million and EPS of US$2.22, setting the tone for how you might read the latest print. Over the past few quarters, total revenue has moved from US$175.6 million in Q4 2024 to US$220.1 million in Q4 2025, while quarterly EPS shifted from US$0.55 to US$0.52. These figures now sit against a trailing twelve month net income of...
NYSE:FHI
NYSE:FHICapital Markets

Federated Hermes Hong Kong Move Puts Asia Growth And Valuation In Focus

Federated Hermes, NYSE:FHI, has received board approval to establish a new office in Hong Kong. The expansion is aimed at serving major financial institutions across Asia more directly. The move marks a material shift in the company’s geographic footprint beyond its existing bases. Federated Hermes, trading at $53.03, is extending its reach into Asia with a Hong Kong office aimed at deepening relationships with large financial institutions. The company has delivered a 37.4% return over the...
NYSE:HZO
NYSE:HZOSpecialty Retail

MarineMax (HZO) Q1 Loss Deepens YoY And Tests Turnaround Bullish Narratives

MarineMax (HZO) opened Q1 2026 with revenue of US$505.2 million and a basic EPS loss of US$0.36, compared with Q1 2025 revenue of US$468.5 million and EPS of US$0.80. Over the intervening quarters, revenue ranged between roughly US$552 million and US$657.2 million. EPS moved from a profit of US$0.15 in Q2 2025 to a larger loss of US$2.42 in Q3 2025, keeping margin pressure firmly in focus for investors trying to make sense of the latest print. See our full analysis for MarineMax. With the...
NasdaqGS:ABCL
NasdaqGS:ABCLLife Sciences

AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets

AbCellera Biologics (NasdaqGS:ABCL) has begun dosing patients in the Phase 2 portion of its Phase 1/2 clinical trial for ABCL635. ABCL635 is a non hormonal candidate for treating moderate to severe vasomotor symptoms associated with menopause. This Phase 2 dosing milestone marks further clinical progress in the company's efforts to develop a potential first in class menopause therapy. AbCellera Biologics, known for its antibody discovery platform, is pushing deeper into clinical development...
NasdaqGM:NRIX
NasdaqGM:NRIXBiotechs

Nurix Therapeutics (NRIX) Q4 Loss Highlights Ongoing Profitability Concerns Despite Revenue Progress

Nurix Therapeutics (NRIX) closed out FY 2025 with Q4 revenue of US$13.6 million and a basic EPS loss of US$0.82, while the trailing twelve months show revenue of US$84.0 million and a basic EPS loss of US$3.05. Over recent periods, the company has seen quarterly revenue range from US$7.9 million to US$44.1 million and basic EPS losses move between US$0.52 and US$1.03 per quarter. This sets the backdrop for what remains an early stage, loss making biotech story. For investors, the key question...
NasdaqGS:EXTR
NasdaqGS:EXTRCommunications

Is Extreme Networks (EXTR) Attractive After Recent Share Price Weakness?

Wondering whether Extreme Networks is priced attractively today or if the recent share moves are a warning sign? This article focuses squarely on what you are getting for the current price. The stock last closed at US$14.37, with returns of a 5.4% decline over the past week, a 14.9% decline over the last month, and a 13.1% decline year to date. The 1 year return is a 7.9% decline and the 3 year return is a 23.6% decline, compared with a 5 year return of 61.1%. Recent attention around Extreme...
NYSE:BIP
NYSE:BIPIntegrated Utilities

Brookfield Infrastructure Partners (NYSE:BIP) Margin Rebound Tests High P/E Bullish Narratives

Brookfield Infrastructure Partners' FY 2025 Earnings Snapshot Brookfield Infrastructure Partners (NYSE:BIP) closed out FY 2025 with fourth quarter revenue of about US$6.3 billion, basic EPS of US$0.40 and net income of US$245 million, putting a spotlight on how its profitability is tracking against expectations. The company has seen revenue move from US$5.4 billion in Q4 2024 to roughly US$6.3 billion in Q4 2025, while basic EPS shifted from US$0.26 to US$0.40 over the same period. This gives...
NYSE:CNMD
NYSE:CNMDMedical Equipment

One Off US$88 Million Loss And Margin Compression Test CONMED (CNMD) Bullish Narratives

CONMED (CNMD) just wrapped up FY 2025 with Q4 revenue of US$373.2 million and basic EPS of US$0.54, alongside trailing twelve month revenue of about US$1.4 billion and EPS of US$1.52. Over the past six quarters in the dataset, revenue has ranged from US$316.7 million to US$373.2 million per quarter, while quarterly EPS has moved between US$0.09 and US$1.59. With trailing net margin sitting at 3.4% versus 10.1% a year earlier, this latest result puts a clear focus on how sustainable the...